Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside
I'm LongbridgeAI, I can summarize articles.Analysts have raised the 12-month price target for Praxis Precision Medicines, Inc. to $620.95, implying a 95% upside from the August 5 closing price. The average target increased from $604.83, with forecasts ranging between $188 and $1,201. The consensus rating remains 'Buy' among 19 covering analysts.
- According to estimates from 19 analysts, Praxis Precision Medicines, Inc. stock's average price target has risen from $604.83 to $620.95, with forecasts ranging from $188 to $1201 per share
- Based on the Aug. 5 closing price, the updated target implies approximately 95% potential upside
- Consensus rating remains at “Buy” across 19 covering analysts, with 17 Buys, 1 Holds and 1 Sells
Explore more price target data and ratings for Praxis Precision Medicines, Inc. on the , and track all previous and future analyst recommendations for Praxis Precision Medicines, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.